Christof Vulsteke

Publicaties Christof Vulsteke

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001) : a randomised, double-blind, placebo-controlled, phase 3 trial

Bron
The lancet oncology - ISSN 1470-2045-27:10 (2026) p. 1221-1236
Auteur(s)
    Ignace Vergote, David Cibula, Matthew Powell, Annouschka Laenen, Els Van Nieuwenhuysen, Samet Topuz, Antonio Gonzalez-Martin, Keiichi Fujiwara, Sufia Safina, Andrea Bagameri, Matthew Oliver, Jung-Yun Lee, Vanda Salutari, Jacob Korach, Chien-Hsing Lu, Radoslaw Madry, Christof Vulsteke, Nicoletta Colombo, Jalid Sehouli, Jaroslav Klat, Eduardo Yanez Ruiz, Lucy Gilbert, Patricia Pautier, Beatriz Pardo, Frederic Kridelka, Jing Wei, Sarper Toker, Karin Yamada, Robert L. Coleman

TKI-associated proteinuria and nephrotic syndrome : a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer

Bron
Acta clinica Belgica - ISSN 1784-3286-81:5 (2026) p. 452-460
Auteur(s)
    Margaux Van Damme, Ximena Elzo-Kraemer, An Deman, Christof Vulsteke, Amelie Dendooven, Liesbeth De Waele

PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer

Bron
The New England journal of medicine - ISSN 0028-4793-395:5 (2026) p. 427-439
Auteur(s)
    Neeraj Agarwal, Nobuaki Matsubara, Arun A. Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D. Shore, Timucin Cil, Christof Vulsteke, Hsiao-Jen Chung, Stefanie Zschabitz, A. Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim Fizazi

Perioperative enfortumab vedotin and pembrolizumab in bladder cancer

Bron
The New England journal of medicine - ISSN 0028-4793-394:13 (2026) p. 1257-1269
Auteur(s)
    Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, Maksym Sabadash, Alejo Rodriguez-Vida, Zhentao Zhang, Vagif Atduev, Y. Emre Goger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke, Matthew D. Galsky, Peter H. O'donnell, Gunhild Von Amsberg, Nimira Alimohamed, Grzegorz Sulimka, Shilpa Gupta, Viktor Paramonov, Keita Nakane, Michael Mihm, Changting Meng, Caizhi David Huang, Chethan Ramamurthy, Blanca Homet Moreno, Anders Ullen

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer : 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial

Bron
International journal of gynecological cancer - ISSN 1048-891X-36:1 (2026) p. 1-7
Auteur(s)
    Christian Marth, Richard G. Moore, Mariusz Bidzi, Vanda Salutari, Ozden Altunda, Maria Jesus Rubio, Tally Levy, Alison Stillie, Christof Vulsteke, Ralf Witteler, Kazuya Ariyoshi, Xiaohua Wu, Sophia Frentzas, Andre Mattar, Brian M. Slomovitz, Stephanie Lheureux, Xiaojun Chen, Kosei Hasegawa, Manuel Magallanes, Chel Hun Choi, Mariia Shalkova, Diego Lucas Kaen, Karen Cadoo, Lili Yao, Jodi Mckenzie, Chinyere E. Okpara, Robin Meng, Robert Orlowski, Lucy Gilbert, Vicky Makker